NCT03904134 (BMT CTN 1702) is a NA clinical trial of Donor Search Prognosis Score in Acute Myeloid Leukemia, sponsored by Center for International Blood and Marrow Transplant Research.

Who is sponsoring NCT03904134?

NCT03904134 is sponsored by Center for International Blood and Marrow Transplant Research.

What drugs are being tested in NCT03904134?

Interventions in NCT03904134: Donor Search Prognosis Score.

What condition does NCT03904134 study?

NCT03904134 studies Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Hodgkin Lymphoma, Acquired Aplastic Anemia, Sickle Cell Disease.

Is NCT03904134 still recruiting?

NCT03904134 is currently completed. Last updated 5 January 2026.

Last reviewed 2026-01-05 · How we verify

NCT03904134: BMT CTN 1702

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)

Completed NA Last updated 5 January 2026

What this trial tests

NA trial testing Donor Search Prognosis Score in Acute Myeloid Leukemia in 1,753 participants. Completed in 6 January 2025.

Timeline

14 June 2019

Primary endpoint
6 January 2025

6 January 2025

Quick facts

Lead sponsor	Center for International Blood and Marrow Transplant Research
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	1,753
Start date	14 June 2019
Primary completion	6 January 2025
Estimated completion	6 January 2025
Sites	52 locations across United States

Drugs / interventions tested

Donor Search Prognosis Score

Conditions studied

Acute Myeloid Leukemia — all drugs for Acute Myeloid Leukemia →
Acute Lymphoblastic Leukemia — all drugs for Acute Lymphoblastic Leukemia →
Myelodysplastic Syndromes — all drugs for Myelodysplastic Syndromes →
Non-hodgkin Lymphoma — all drugs for Non-hodgkin Lymphoma →

Sponsor

Center for International Blood and Marrow Transplant Research — full company profile →

Who can join

Eligibility, any sex, with Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to determine if a search strategy of searching for an HLA-matched unrelated donor for allogeneic transplantation if possible then an alternative donor if an HLA-matched unrelated donor is not available versus proceeding directly to an alternative donor transplant will result in better survival for allogeneic transplant recipients within 2 years after study enrollment.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Improved GRFS after posttransplant cyclophosphamide-based vs ATG-based HLA-mismatched unrelated donor transplant.
Jimenez Jimenez A, Komanduri K, Brown S, Wang T, et al · · 2022 · cited 24× · PMID 35793451 · DOI 10.1182/bloodadvances.2022007596
Hematology 2022-what is complete HLA match in 2022?
Spellman SR. · · 2022 · cited 22× · PMID 36485162 · DOI 10.1182/hematology.2022000326
Access to Allogeneic Cell Transplantation Based on Donor Search Prognosis: BMT CTN 1702 Trial.
Dehn JG, Logan B, Lee SJ, Shaw BE, et al · · 2026 · cited 3× · PMID 41213499 · DOI 10.1016/j.jtct.2025.11.010

Verify or expand the search:

Other recruiting trials for Acute Myeloid Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06782542 — Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for I · Phase 2 · recruiting
NCT07177079 — High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML · Phase 1 · recruiting
NCT07384715 — First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelod · Phase 1 · recruiting
NCT07107126 — Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes · Phase 1 · recruiting

Other Center for International Blood and Marrow Transplant Research trials

Trials by the same sponsor.

NCT06001385 — HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cycloph · Phase 2 · active not recruiting
NCT05224661 — Molecular Evaluation of AML Patients After Stem Cell Transplant to Understand Relapse Events · active not recruiting
NCT03992352 — Composite Health Assessment Risk Model (CHARM) for Older Adults (BMT CTN 1704) · completed
NCT03718546 — Identifying Predictors of Poor Health-Related Quality-of-Life Among Pediatric Hematopoietic Stem Cell Donors · completed
NCT03619551 — Conditioning SCID Infants Diagnosed Early · Phase 2 · active not recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03904134 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Center for International Blood and Marrow Transplant Research
Last refreshed: 5 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03904134.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing